Aprea Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 7
- Market Cap
- $19.1M
- Website
- http://www.aprea.com
- Introduction
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Study of APR-1051 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 79
- Registration Number
- NCT06260514
- Locations
- 🇺🇸
MD Anderson Cancer Center (MDACC), Houston, Texas, United States
🇺🇸NEXT Oncology -Dallas, Irving, Texas, United States
🇺🇸NEXT Oncology -San Antonio, San Antonio, Texas, United States
Study Of ATRN-119 In Patients With Advanced Solid Tumors
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT04905914
- Locations
- 🇺🇸
NEXT- Oncology Dallas, Irving, Texas, United States
🇺🇸NEXT Oncology- San Antonio, San Antonio, Texas, United States
🇺🇸NEXT Oncology- Virginia, Fairfax, Virginia, United States
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT04638309
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institue, Boston, Massachusetts, United States
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
- Conditions
- Chronic Lymphocytic LeukemiaMantle Cell LymphomaNon Hodgkin Lymphoma
- Interventions
- Drug: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLLDrug: APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RTDrug: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT04419389
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
- Conditions
- NSCLCUrothelial CarcinomaBladder CancerAdvanced Solid TumorGastric CancerNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT04383938
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Center, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- Next
News
Halda Therapeutics Appoints Dr. Eyal Attar as Chief Medical Officer to Advance Novel RIPTAC Cancer Platform
• Dr. Eyal Attar joins Halda Therapeutics as Chief Medical Officer, bringing over 25 years of biotechnology R&D and clinical trial experience to advance the company's novel RIPTAC cancer therapy platform. • Halda is currently conducting a Phase 1/2 clinical trial of HLD-0915, their lead candidate targeting metastatic castration-resistant prostate cancer (mCRPC) through a unique "hold and kill" mechanism designed to overcome resistance. • The RIPTAC platform represents a new therapeutic modality that creates neomorphic protein-protein interactions to selectively target cancer cells, with programs in development for prostate cancer, breast cancer, and other serious diseases.
Aprea Therapeutics Advances APR-1051 Clinical Trial with First HPV+ Head and Neck Cancer Patient Dosed
Aprea Therapeutics has dosed the first HPV+ head and neck squamous cell carcinoma (HNSCC) patient in Cohort 5 of the ACESOT-1051 trial, evaluating their WEE1 kinase inhibitor APR-1051.
Aprea Therapeutics Optimizes ATRN-119 Dosing in Phase 1/2a Trial for Advanced Solid Tumors
• Aprea Therapeutics initiates twice-daily dosing of ATRN-119 at 550mg in the ABOYA-119 Phase 1/2a trial to maintain optimal therapeutic levels. • The trial evaluates ATRN-119 as a monotherapy for advanced solid tumors with DNA damage response gene mutations, potentially enhancing efficacy. • Phase 1 readout is anticipated in the second half of 2025, with dose escalation continuing independently for both once-daily and twice-daily schedules. • ATRN-119 is the first macrocyclic ATR inhibitor in clinical trials and the only one tested as a monotherapy on a continuous twice-daily schedule.
Aprea Therapeutics Advances WEE1 and ATR Inhibitors in Clinical Trials
Aprea Therapeutics is progressing its Phase 1 ACESOT-1051 trial of APR-1051, a WEE1 inhibitor, showing promising tolerability in treating cancers with Cyclin E over-expression.